Cancer Drug Shortages | sciencenewsnet.in

Breaking News

Additional comments on extracellular vesicles derived from mesenchymal stem cells mediate extracellular matrix remodeling in osteoarthritis

Wharton’s jelly mesenchymal stem cells: Future regenerative medicine for clinical applications in mitigation of radiation injury

Current perspectives on mesenchymal stem cells as a potential therapeutic strategy for non-alcoholic fatty liver disease

Study finds targeting inflammation may not help reduce liver fibrosis in MAFLD

UF scientists study how to bring you ‘climate-smart coffee’

Moffitt Study Uncovers Key Immune Cells for Combating Aggressive Merkel Cell Carcinoma

Chula hosted “The Second Chulalongkorn University President’s Distinguished Speakers” a Special Lecture on “Revolutionizing the Future: An Exclusive Talk with “Andrew Ng” on Opportunities and Business Preparedness” by the World’s Influential AI Exper

Cleaning the window of opportunity: Towards a typology of sustainability entrepreneurs

Does information disclosure alleviate overcrowding? An empirical study based on large-scale COVID-19 nucleic acid test

Researchers develop state-of-the-art device to make artificial intelligence more energy efficient

26 Jul, 2024

New Survey from NCCN Finds Cancer Drug Shortage Management Remains a Moving Target, Impacting Clinical Trials

June 26, 2024 sarah JonasAnnouncement

NCCN shares new data on continued high prevalence for cancer drug shortages in the United States. In the latest survey, carboplatin and cisplatin shortages fell to 11% and 7% respectively, but 89% of centers surveyed continue to report shortages for at least one type of systemic therapy; 75% are experiencing two or more drug shortages.

U.S. Cancer Centers Continue to See Chemotherapy Shortages, According to Update from NCCN

October 5, 2023 sarah JonasResearch Results

72% of the centers surveyed by NCCN continue to experience a shortage of carboplatin and 59% are still seeing a shortage of cisplatin. Overall, 86% of centers surveyed reported experiencing a shortage of at least one type of anti-cancer drug.